Ovid Therapeutics Inc OVID.OQ OVID.O is expected to show a fall in quarterly revenue when it reports results on August 11 (estimated) for the period ending June 30 2025
The New York City-based company is expected to report a 54.6% decrease in revenue to $76.67 thousand from $169 thousand a year ago, according to the mean estimate from 6 analysts, based on LSEG data.
LSEG's mean analyst estimate for Ovid Therapeutics Inc is for a loss of 16 cents per share.
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Ovid Therapeutics Inc is $3.00, about 83% above its last closing price of $0.51
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | -0.14 | -0.14 | -0.14 | Met | -2.4 |
Dec. 31 2025 | -0.17 | -0.17 | -0.13 | Beat | 21.7 |
Sep. 30 2024 | -0.19 | -0.20 | -0.20 | Met | 1.9 |
Jun. 30 2024 | -0.20 | -0.22 | 0.12 | Beat | 154.1 |
Mar. 31 2024 | -0.22 | -0.22 | -0.17 | Beat | 22 |
Dec. 31 2023 | 0.25 | -0.05 | -0.22 | Missed | -342.6 |
Sep. 30 2023 | -0.19 | -0.19 | -0.16 | Beat | 15.2 |
Jun. 30 2023 | -0.20 | -0.20 | -0.18 | Beat | 12 |
This summary was machine generated August 8 at 17:42 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)